EUVIMEDTutustu EUVIMEDiin
Randomisierte kontrollierte Studie

Personalized or Standard Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: PARTHENOPE Randomized Trial.

Raffaele Piccolo, Calabrò, Paolo, Greta Carrara, Fiorenzo Simonetti, Attilio Varricchio, Tiziana Attisano, Giovanni Napolitano, Ciro De Simone, Gerardo Carpinella, Eugenio Stabile, Plinio Lorenzo Cirillo and 33 more

Open Access CRIS of the University of Bern · 2025-12-09

DOI: 10.48620/91086 ↗

At a glance

Randomisierte kontrollierte Studie in Open Access CRIS of the University of Bern, published on 2025-12-09. Written by Raffaele Piccolo and 44 co-authors.

TiivistelmäSubjectsBibliografiset tiedotCiteRelated studies

Abstract (original language)

Background

Dual antiplatelet therapy (DAPT) is recommended for patients undergoing percutaneous coronary intervention (PCI), although its optimal duration remains uncertain.

Objectives

We performed a randomized trial comparing a personalized duration of DAPT, based on a risk score, for 3-, 6-, or 24-months with a standard duration of DAPT for 12 months after PCI.

Methods

We randomly assigned 2,107 patients undergoing PCI to receive either a personalized or a standard DAPT. The primary end point was a net adverse clinical end point (NACE) at 24-months, defined as the composite of all-cause death, myocardial infarction, stroke, urgent target-vessel revascularization, or type 2, 3, or 5 bleeding according to the Bleeding Academic Research Consortium (BARC) criteria. The trial was registered in ClinicalTrials.gov (NCT04135989) RESULTS: At 24-months, NACE occurred in 196 of 1,055 patients (18.6%) in the personalized DAPT group and in 232 of 1,052 patients (22.2%) in the standard DAPT group (difference, 3.54 percentage points, 95% confidence interval [CI], -6.99 to -0.99; P=0.040). This difference was mainly related to decreased rates of myocardial infarction (difference, -2.29 percentage points, 95% CI, -4.43 to -0.14) and urgent target-vessel revascularization (difference, -1.30 percentage points, 95% CI, -2.55 to -0.05). Bleeding occurred at similar rates between the two groups (difference, -0.41 percentage points; 95% confidence interval [CI], -2.92 to 2.10).

Conclusions

In patients undergoing PCI, a personalized DAPT duration from 3 to 24 months based on a clinical risk score led to a lowered risk of net adverse clinical events than standard care consisting of 12 months of DAPT.

Subjects

dual antiplatelet therapyDAPT durationpercutaneous coronary interventionclinical risk scorenet adverse clinical eventsmyocardial infarctiontarget vessel revascularizationhemorrhageall-cause mortalitystroke

Cite

APA

Piccolo, R., Calabrò, Paolo, Carrara, G., Simonetti, F., Varricchio, A., Attisano, T., Napolitano, G., Simone, C. D., Carpinella, G., Stabile, E., Cirillo, P. L., Serafino, L. D., Caiazzo, G., Tesorio, T., Boccalatte, M., Tuccillo, B., Avvedimento, M., Leone, A., …, & Giovanni (2025). Personalized or Standard Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: PARTHENOPE Randomized Trial. Open Access CRIS of the University of Bern. https://doi.org/10.48620/91086

Vancouver

Piccolo R, Calabrò, Paolo, Carrara G, Simonetti F, Varricchio A, et al. Personalized or Standard Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: PARTHENOPE Randomized Trial. Open Access CRIS of the University of Bern. 2025. doi:10.48620/91086

BibTeX
@article{Piccolo2025,
  author = {Piccolo, Raffaele and Calabrò and Paolo and Carrara, Greta and Simonetti, Fiorenzo and Varricchio, Attilio and Attisano, Tiziana and Napolitano, Giovanni and Simone, Ciro De and Carpinella, Gerardo and Stabile, Eugenio and Cirillo, Plinio Lorenzo and Serafino, Luigi Di and Caiazzo, Gianluca and Tesorio, Tullio and Boccalatte, Marco and Tuccillo, Bernardino and Avvedimento, Marisa and Leone, Attilio and Galasso, Gennaro and Cesaro, Arturo and Perrotta, Rocco and Niglio, Tullio and Castiello, Domenico Simone and Molaro, Maddalena Immobile and Bardi, Luca and Spinelli, Alessandra Maria and Cristiano, Stefano and Bellino and Michele and Leonardi and Sergio and Biscaglia, Simone and Costa and Francesco and Cassese, Salvatore and McFadden, Eugene Patrick and Heg, Dik and Stefanini and G, Giulio and Franzone, Anna and Capodanno and Davide and Esposito and Giovanni},
  title = {Personalized or Standard Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: PARTHENOPE Randomized Trial},
  journal = {Open Access CRIS of the University of Bern},
  year = {2025},
  doi = {10.48620/91086}
}
Start for free →